Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.
Aprogen Pharmaceuticals Inc (003060) - Total Liabilities
Latest total liabilities as of September 2025: ₩288.27 Billion KRW
Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has total liabilities worth ₩288.27 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aprogen Pharmaceuticals Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aprogen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Central Motek Co Ltd
KO:308170
|
Korea | ₩241.04 Billion |
|
MARKEL CORP (MKV.SG)
STU:MKV
|
Germany | €44.62 Billion |
|
Gamehaus Holdings Inc. Class A Ordinary Shares
NASDAQ:GMHS
|
USA | $12.99 Million |
|
Goodfood Market Corp
PINK:GDDFF
|
USA | $68.44 Million |
|
Plantynet Co. Ltd
KQ:075130
|
Korea | ₩15.47 Billion |
|
Giyani Metals Corp
PINK:CATPF
|
USA | $40.22 Million |
|
Global Education Limited
NSE:GLOBAL
|
India | ₹135.55 Million |
|
Dongyang Piston Co Ltd
KO:092780
|
Korea | ₩283.87 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Aprogen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aprogen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aprogen Pharmaceuticals Inc (2009–2024)
The table below shows the annual total liabilities of Aprogen Pharmaceuticals Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩212.29 Billion | -3.81% |
| 2023-12-31 | ₩220.71 Billion | +27.04% |
| 2022-12-31 | ₩173.73 Billion | +896.14% |
| 2021-12-31 | ₩17.44 Billion | +2.87% |
| 2020-12-31 | ₩16.95 Billion | -3.93% |
| 2019-12-31 | ₩17.65 Billion | -73.49% |
| 2018-12-31 | ₩66.55 Billion | -17.24% |
| 2017-12-31 | ₩80.41 Billion | +59.01% |
| 2016-12-31 | ₩50.57 Billion | +189.37% |
| 2015-12-31 | ₩17.48 Billion | -23.06% |
| 2014-12-31 | ₩22.71 Billion | +4.62% |
| 2013-12-31 | ₩21.71 Billion | -11.65% |
| 2012-12-31 | ₩24.58 Billion | -42.64% |
| 2011-12-31 | ₩42.85 Billion | +19.37% |
| 2010-12-31 | ₩35.89 Billion | +36.66% |
| 2010-09-30 | ₩26.26 Billion | -22.50% |
| 2009-12-31 | ₩33.89 Billion | -- |